The finding that there is a significant reduction in biomarkers of type 1 diabetes mellitus and accompanying insulin requirements arguably supersedes the traditional paradigm that these operations are only for type 2 diabetes mellitus as they cannot reverse the inherent pancreaopathy of T1DM. This evidence concerns the gene INS and type 2 diabetes mellitus.